Darwin Global Management 13F annual report

Darwin Global Management is an investment fund managing more than $366 billion ran by John Legge. There are currently 4 companies in Mr. Legge’s portfolio. The largest investments include TG Therapeutics Inc and Argenx Se, together worth $263 billion.

$366 billion Assets Under Management (AUM)

As of 7th August 2023, Darwin Global Management’s top holding is 10,451,241 shares of TG Therapeutics Inc currently worth over $157 billion and making up 43.0% of the portfolio value. Relative to the number of outstanding shares of TG Therapeutics Inc, Darwin Global Management owns less than approximately 0.1% of the company. In addition, the fund holds 285,198 shares of Argenx Se worth $106 billion. The third-largest holding is Ambrx Biopharma worth $101 billion and the next is Keros Therapeutics worth $1.34 billion, with 31,386 shares owned.

Currently, Darwin Global Management's portfolio is worth at least $366 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Darwin Global Management

The Darwin Global Management office and employees reside in St. Helier, Jersey. According to the last 13-F report filed with the SEC, John Legge serves as the Chief Financial Officer and Chief Compliance Officer at Darwin Global Management.

Recent trades

In the most recent 13F filing, Darwin Global Management revealed that it had opened a new position in TG Therapeutics Inc and bought 10,451,241 shares worth $157 billion.

On the other hand, there are companies that Darwin Global Management is getting rid of from its portfolio. Darwin Global Management closed its position in Astrazeneca plc on 14th August 2023. It sold the previously owned 2,849,109 shares for $188 million.

One of the average hedge funds

The two most similar investment funds to Darwin Global Management are Stewart & Patten Co and Jgp Wealth Management. They manage $612 billion and $611 billion respectively.

John Legge investment strategy

Darwin Global Management’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 70.9% of the total portfolio value. The fund focuses on investments in the United States as 75.0% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are small-cap stocks. Stocks with a size of more than $100 million in market cap make up 25% of the total holdings value. On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $801 million.

The complete list of Darwin Global Management trades based on 13F SEC filings

These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
TG Therapeutics Inc	Opened 10,451,241	$157,186,665,000	42.99%
Argenx Se	Opened 285,198	$106,259,071,000	29.06%
Ambrx Biopharma Inc.	Opened 11,304,573	$100,836,791,000	27.58%
Keros Therapeutics, Inc.	Opened 31,386	$1,340,182,000	0.37%
Astrazeneca plc	Closed 2,849,109	$188,241,000
No transactions found
Showing first 500 out of 5 holdings